secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001437749-24-014382
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotech Q1 net loss $4.8M vs prior year net income; NERLYNX revenue down 14%
--------------------------------------------------------------------------------

- Net product revenue $40.3M (Q1 2023: $46.8M); total revenue $43.8M including $3.5M royalties.
- GAAP net loss $0.10/shr; non-GAAP adjusted net loss $0.05/shr vs adjusted net income $0.09/shr in Q1 2023.
- Cash, cash equivalents and marketable securities $107.2M at March 31, 2024; operating cash flow $11.3M.
- Q2 2024 guidance: net product revenue $43-45M, net loss $(6)-(9)M; FY2024: product revenue $183-190M, net income $12-15M.
- Initiated alisertib Phase II trial in small cell lung cancer (ALISCA-Lung1); key milestones through Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924014382/0001437749-24-014382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924014382/pbyi20240430_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-014382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer